Cytoreduction-Adapted Outpatient Venetoclax Ramp-Up in CLL/SLL: A Real-World Pilot Study
Lymphatics · 30.07.2026 · 4 (3) · 40
DOI: 10.3390/lymphatics4030040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lymphatics, online erschienen am 30.07.2026. Verfasst von Monica Wallin und 7 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense.
Abstract (Originalsprache)
Venetoclax-based therapy is effective in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), but tumor lysis syndrome (TLS) risk necessitates a resource-intensive five-week dose ramp-up with intravenous hydration, frequent laboratory monitoring, and clinic-based observation, creating logistical barriers particularly in community settings. We conducted a single-center, IRB-approved retrospective pilot study of 30 patients with CLL/SLL who underwent a cytoreduction-adapted, IV-free outpatient venetoclax ramp-up with reduced laboratory monitoring between 2023 and 2026. All patients received cytoreductive therapy—predominantly single-agent BTKi—and met protocol-defined low-tumor-burden criteria (ALC < 20 × 109/L, lymph nodes < 5 cm, no splenomegaly, CrCl > 45 mL/min) before venetoclax initiation. Venetoclax was self-administered at home with laboratory monitoring reduced to a single approximately 12-h post-dose assessment per dose-escalation week. Median age was 71 years; 80% had received ≥2 prior therapy lines, and 37% had high-risk cytogenetics. Monitoring compliance was 100%. No laboratory or clinical TLS, IV hydration, hospitalizations, dose interruptions, treatment discontinuations, or deaths occurred during ramp-up. These pilot data support the feasibility and early safety of simplified outpatient venetoclax initiation in adequately cytoreduced patients and warrant prospective multicenter validation.
Förderung
- U.S. Department of Defense
Zitieren
APA
Wallin, M., Rampersaud, T., Ko, S., Atiq, R., Boisclair, S., Shih, A., Gladstone, D. E., & Shah, P. (2026). Cytoreduction-Adapted Outpatient Venetoclax Ramp-Up in CLL/SLL: A Real-World Pilot Study. Lymphatics, 4(3), 40. https://doi.org/10.3390/lymphatics4030040
Vancouver
Wallin M, Rampersaud T, Ko S, Atiq R, Boisclair S, Shih A, et al. Cytoreduction-Adapted Outpatient Venetoclax Ramp-Up in CLL/SLL: A Real-World Pilot Study. Lymphatics. 2026;4(3):40. doi:10.3390/lymphatics4030040
BibTeX
@article{Wallin2026,
author = {Wallin, Monica and Rampersaud, Teshmanie and Ko, Sally and Atiq, Rizwan and Boisclair, Stephanie and Shih, Andrew and Gladstone, Douglas E. and Shah, Pratik},
title = {Cytoreduction-Adapted Outpatient Venetoclax Ramp-Up in CLL/SLL: A Real-World Pilot Study},
journal = {Lymphatics},
year = {2026},
volume = {4},
number = {3},
pages = {40},
doi = {10.3390/lymphatics4030040}
}
EUVIMED